Additionally, vorasidenib, an IDH1/IDH2 inhibitor, has shown efficacy in extending progression-free survival in patients with IDH-mutant gliomas, providing an opportunity to delay treatments like radiation and chemotherapy, thus preserving cognitive function [22,23]. This evidence concerns the gene IDH1 and central nervous system cancer.